J.P. Morgan Maintains Buy Rating and Sets $70 Price Target for First Tracks Biotherapeutics
J.P. Morgan analyst Anupam Rama has reaffirmed a 'Buy' rating on First Tracks Biotherapeutics, Inc. (TRAX) and established a price target of $70.
Stocks · News reference
First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
J.P. Morgan analyst Anupam Rama has reaffirmed a 'Buy' rating on First Tracks Biotherapeutics, Inc. (TRAX) and established a price target of $70.
First Tracks Biotherapeutics was named as one of the top 30 small employers in the life sciences industry in BioSpace's 2027 Best Places to Work list.
Guggenheim analyst Yatin Suneja maintained a 'Buy' rating on First Tracks Biotherapeutics and increased the price target from $100 to $110.
Analysts have raised the 12-month price target for First Tracks Biotherapeutics to $75, reflecting a potential 62% upside based on recent closing prices.
First Tracks Biotherapeutics announced that its executive team will participate in several investor conferences throughout November and December 2026.
First Tracks Biotherapeutics reported its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline, including positive Phase 1b data for ANB033.